HealthcareServices

Chronic Myeloid Leukemia (CML) Treatment Market Trends and Insights: Global Forecast to 2030

February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the chronic myeloid leukemia (cml) treatment market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Chronic Myeloid Leukemia (CML) Treatment Market covering 2026–2035?

The chronic myeloid leukemia (cml) treatment market has experienced significant growth in recent years. Its value is expected to rise from $8.64 billion in 2025 to $9.23 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. This historical expansion can be attributed to several factors including improved diagnostic precision for hematological cancers, greater availability of first-generation TKIs, increased awareness of CML, the development of more oncology treatment centers, and enhanced patient survival rates.

The chronic myeloid leukemia (cml) treatment market is projected to experience robust expansion in the coming years. This market is set to reach $12.17 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.2%. The anticipated growth during this period is largely driven by factors such as the accelerated development of new targeted agents, the rising uptake of combination therapies, the broadening of precision oncology initiatives, a heightened emphasis on patient adherence to treatment, and increased financial commitments to oncology research. Key trends anticipated for the forecast timeframe involve a greater embrace of targeted therapy regimens, an increased utilization of next-generation TKIs, a heightened focus on molecular diagnostics, the expansion of individualized treatment protocols, and a stronger emphasis on managing the disease over the long term.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12084&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Chronic Myeloid Leukemia (CML) Treatment Market?

The increasing occurrence and widespread presence of the chronic myeloid leukemia (CML) population are projected to stimulate the expansion of the chronic myeloid leukemia (CML) treatment market in the future. Chronic myeloid leukemia, also referred to as chronic myelogenous leukemia, is a malignancy impacting the bone marrow and blood. This condition is defined by an excessive generation of immature white blood cells known as myeloid cells. Treatment for chronic myeloid leukemia (CML) aids in decelerating the disease’s advancement and preventing it from progressing to a later stage. For example, in March 2023, the American Society of Clinical Oncology, a US-based professional body representing physicians of all oncology sub-specialties, reported that in the United States, approximately 35,730 persons (19,860 men and 15,870 women) are forecast to be diagnosed with multiple myeloma in 2023, with an estimated 12,590 deaths from this illness also in 2023 (7,000 males and 5,590 women). Consequently, the increased incidence and prevalence of the chronic myeloid leukemia (CML) population are propelling the expansion of the chronic myeloid leukemia (CML) treatment market moving forward.

What Segments Are Identified Within The Structure Of The Chronic Myeloid Leukemia (CML) Treatment Market?

The chronic myeloid leukemia (cml) treatment market covered in this report is segmented –

1) By Type: Targeted Therapy, Chemotherapy, Radiation Therapy, Splenectomy, Stem Cell Transplant

2) By Drug Type: Tyrosine Kinase Inhibitors, Antimetabolites, Other Drug Types

3) By Application: Hospitals, Clinic, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), BCR-ABL Inhibitors, Monoclonal Antibody Therapy, Signal Transduction Inhibitors

2) By Chemotherapy: Alkylating Agents, Antimetabolites, Anthracyclines, Combination Chemotherapy Regimens

3) By Radiation Therapy: External Beam Radiation Therapy, Total Body Irradiation, Radioimmunotherapy

4) By Splenectomy: Partial Splenectomy, Total Splenectomy

5) By Stem Cell Transplant: Allogeneic Hematopoietic Stem Cell Transplant, Autologous Stem Cell Transplant

Which Trends Are Guiding The Evolution Of The Chronic Myeloid Leukemia (CML) Treatment Market?

Leading entities within the chronic myeloid leukemia (CML) treatment sector are prioritizing strategic alliances and cooperative ventures to broaden their product offerings, expedite market entry, and extend their global presence. These collaborations allow biotechnology firms to utilize specific knowledge in areas such as market penetration, regulatory navigation, and oncology product commercialization, thereby delivering novel treatments to patients more effectively. As an illustration, during February 2023, Xspray Pharma, a biotechnology enterprise based in Sweden, formed an alliance with EVERSANA, a U.S.-headquartered life sciences commercialization organization. This partnership aims to facilitate the U.S. introduction and market development of Dasynoc (XS004), a therapeutic agent targeting chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL). Dasynoc represents a distinct and novel treatment option, currently awaiting FDA approval and subject to legal conditions, poised to enter the approximately $3.5 billion U.S. market dedicated to tyrosine kinase inhibitors. This collaboration will provide Xspray Pharma with entry to EVERSANA’s specialized oncology commercialization team, facilitating the development of a tailored and streamlined strategy for market penetration. Scheduled for introduction in the second half of 2023, Dasynoc is projected to substantially enhance the therapeutic choices available to patients suffering from CML and ALL across the United States.

Which Major Firms Are Strengthening Their Position In The Chronic Myeloid Leukemia (CML) Treatment Market?

Major companies operating in the chronic myeloid leukemia (cml) treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Incyte Corporation, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Innovent Biologics Inc., Glenmark Pharmaceuticals Limited, Il-Yang Pharmaceutical Co. Ltd., Accord Healthcare Inc., ARIAD Pharmaceuticals Inc., Orca Bio, Bio-Path Holdings Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/chronic-myeloid-leukemia-cml-treatment-global-market-report

Which Regions Are Poised For Strategic Growth In The Chronic Myeloid Leukemia (CML) Treatment Market?

North America was the largest region in the chronic myeloid leukemia (CML) treatment market in 2025. The regions covered in the chronic myeloid leukemia (cml) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Chronic Myeloid Leukemia (CML) Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12084&type=smp

Browse Through More Reports Similar to the Global Chronic Myeloid Leukemia (CML) Treatment Market 2026, By The Business Research Company

Leukemia Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Chronic Myeloid Leukemia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-myeloid-leukemia-treatment-global-market-report

Chronic Myeloid Leukemia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-myeloid-leukemia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795